CR20200539A - Receptores quiméricos de dll3 y métodos para su uso - Google Patents

Receptores quiméricos de dll3 y métodos para su uso

Info

Publication number
CR20200539A
CR20200539A CR20200539A CR20200539A CR20200539A CR 20200539 A CR20200539 A CR 20200539A CR 20200539 A CR20200539 A CR 20200539A CR 20200539 A CR20200539 A CR 20200539A CR 20200539 A CR20200539 A CR 20200539A
Authority
CR
Costa Rica
Prior art keywords
dll3
methods
chimeric receptors
immune cells
binding molecules
Prior art date
Application number
CR20200539A
Other languages
English (en)
Spanish (es)
Inventor
Melissa Thomas
Lawren Wu
Ruben Alvarez Rodriguez
Jun Feng
Christopher Murawsky
Michael John Giffin
Jed Wiltzius
Ryan Benjamin Case
Original Assignee
Kite Pharma Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc, Amgen Inc filed Critical Kite Pharma Inc
Publication of CR20200539A publication Critical patent/CR20200539A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR20200539A 2018-04-10 2019-04-10 Receptores quiméricos de dll3 y métodos para su uso CR20200539A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655725P 2018-04-10 2018-04-10
PCT/US2019/026840 WO2019200007A1 (en) 2018-04-10 2019-04-10 Chimeric receptors to dll3 and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20200539A true CR20200539A (es) 2021-07-01

Family

ID=66248863

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200539A CR20200539A (es) 2018-04-10 2019-04-10 Receptores quiméricos de dll3 y métodos para su uso

Country Status (27)

Country Link
US (1) US12012462B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773912A1 (cg-RX-API-DMAC7.html)
JP (1) JP7479290B2 (cg-RX-API-DMAC7.html)
KR (1) KR102951376B1 (cg-RX-API-DMAC7.html)
CN (1) CN112334193A (cg-RX-API-DMAC7.html)
AR (1) AR114283A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019251473A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020020857A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095920A1 (cg-RX-API-DMAC7.html)
CL (3) CL2020002613A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020013392A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200539A (cg-RX-API-DMAC7.html)
EA (1) EA202092417A1 (cg-RX-API-DMAC7.html)
IL (1) IL277735B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20200259A1 (cg-RX-API-DMAC7.html)
MA (1) MA52203A (cg-RX-API-DMAC7.html)
MX (1) MX2020010753A (cg-RX-API-DMAC7.html)
MY (1) MY203383A (cg-RX-API-DMAC7.html)
PE (1) PE20211396A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551671A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420301B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009923TA (cg-RX-API-DMAC7.html)
TW (1) TWI842703B (cg-RX-API-DMAC7.html)
UA (1) UA129466C2 (cg-RX-API-DMAC7.html)
UY (2) UY41150A (cg-RX-API-DMAC7.html)
WO (1) WO2019200007A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006943B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
EP4527466A3 (en) 2019-07-17 2025-06-18 Legend Biotech Ireland Limited Anti-dll3 chimeric antigen receptors and uses thereof
US20230272035A1 (en) * 2019-12-05 2023-08-31 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2021180215A1 (en) 2020-03-12 2021-09-16 Nanjing Legend Biotech Co., Ltd. Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
US20240150456A1 (en) * 2021-04-02 2024-05-09 Nanjing Legend Biotech Co., Ltd. Engineered immune cells and uses thereof
US20240239878A1 (en) * 2021-05-08 2024-07-18 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Binding molecule against dll3 and use thereof
WO2022240688A1 (en) * 2021-05-10 2022-11-17 Amgen Inc. Dosing regimen for combination therapy targeting dll3 and pd-1
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
CA3230627A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
CA3245384A1 (en) 2022-03-03 2023-09-07 Cambridge Enterprise Limited Therapeutic antibodies
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
WO2023199069A1 (en) 2022-04-14 2023-10-19 Crescendo Biologics Limited Chimeric antigen receptor that binds mesothelin
WO2024026284A2 (en) * 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
CN116003628B (zh) * 2022-08-15 2026-08-04 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
KR20260079181A (ko) * 2023-09-26 2026-06-01 레전드 바이오테크 유에스에이, 인크. Dll3 결합 모이어티 및 이의 용도
CN122094981A (zh) * 2023-10-16 2026-05-26 上海先博生物科技有限公司 一种靶向δ样配体3的CAR及应用
GB202402046D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
GB202402048D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
WO2025202653A1 (en) 2024-03-27 2025-10-02 Ucl Business Ltd T-cell therapy targetting mutant calreticulin
WO2026039940A1 (zh) * 2024-08-19 2026-02-26 南京博安生物技术有限公司 一种增强型靶向dll3蛋白的嵌合抗原受体和突变体以及应用
GB202412771D0 (en) 2024-08-30 2024-10-16 Cambridge Entpr Ltd Therapeutic molecules
CN119241712B (zh) * 2024-12-05 2025-05-06 晟临生物医药(上海)有限公司 抗dll3的纳米抗体、嵌合抗原受体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9024028B2 (en) 2011-01-26 2015-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for the synthesis of multimerizing agents
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
JP6267644B2 (ja) * 2011-10-20 2018-01-24 アメリカ合衆国 抗cd22キメラ抗原受容体
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
AU2017240801A1 (en) * 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
KR20210018797A (ko) 2021-02-18
TW202011999A (zh) 2020-04-01
KR102951376B1 (ko) 2026-04-13
SG11202009923TA (en) 2020-11-27
WO2019200007A1 (en) 2019-10-17
AR114283A1 (es) 2020-08-12
AU2026200393A1 (en) 2026-04-09
UY41150A (es) 2025-09-30
CL2020002613A1 (es) 2020-12-28
EP3773912A1 (en) 2021-02-17
IL277735A (en) 2020-11-30
CO2020013392A2 (es) 2020-11-10
UA129466C2 (uk) 2025-05-07
JP2021520788A (ja) 2021-08-26
ZA202006943B (en) 2025-08-27
IL277735B1 (en) 2026-06-01
SA520420301B1 (ar) 2024-08-05
CL2023000896A1 (es) 2023-11-03
JOP20200259A1 (ar) 2020-10-11
BR112020020857A2 (pt) 2021-01-19
MX2020010753A (es) 2021-01-29
UY38182A (es) 2019-10-31
PE20211396A1 (es) 2021-07-27
MA52203A (fr) 2021-02-17
EA202092417A1 (ru) 2021-01-26
TWI842703B (zh) 2024-05-21
AU2019251473A1 (en) 2020-10-22
JP7479290B2 (ja) 2024-05-08
US20210163621A1 (en) 2021-06-03
US12012462B2 (en) 2024-06-18
CN112334193A (zh) 2021-02-05
PH12020551671A1 (en) 2021-06-07
CA3095920A1 (en) 2019-10-17
CL2023000895A1 (es) 2023-11-03
MY203383A (en) 2024-06-26

Similar Documents

Publication Publication Date Title
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2022001873A1 (es) Receptores quiméricos y metodos de uso de los mismos
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX389710B (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
SG10201901057UA (en) Anti-pd-l1 antibodies
MX388181B (es) Anticuerpos anti-pd-1.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201892440A1 (ru) Антитела к tl1a и их применения
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
CL2023003182A1 (es) Receptores químericos de steap1 y métodos de uso de los mismos
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека